# A Phase 3 Study to Compare Upadacitinib to Abatacept in Subjects With Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease- Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response or Intolerance to Biologic DMARDs

> **NCT03086343** · PHASE3 · COMPLETED · sponsor: **AbbVie** · enrollment: 657 (actual)

## Conditions studied

- Rheumatoid Arthritis (RA)

## Interventions

- **DRUG:** Abatacept
- **DRUG:** Placebo for abatacept (0.9% Sodium Chloride Injection or Solution for Infusion)
- **DRUG:** Upadacitinib
- **DRUG:** Placebo for upadacitinib

## Key facts

- **NCT ID:** NCT03086343
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-05-09
- **Primary completion:** 2019-06-13
- **Final completion:** 2023-06-06
- **Target enrollment:** 657 (ACTUAL)
- **Last updated:** 2024-07-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03086343

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03086343, "A Phase 3 Study to Compare Upadacitinib to Abatacept in Subjects With Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease- Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response or Intolerance to Biologic DMARDs". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT03086343. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*